NASDAQ:BDSX Biodesix (BDSX) Stock Price, News & Analysis $1.30 -0.40 (-23.53%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Biodesix Stock (NASDAQ:BDSX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Biodesix alerts:Sign Up Key Stats Today's Range$1.28▼$1.6750-Day Range$1.30▼$1.9652-Week Range$1.15▼$2.21Volume554,657 shsAverage Volume149,748 shsMarket Capitalization$188.73 millionP/E RatioN/ADividend YieldN/APrice Target$3.06Consensus RatingBuy Company OverviewBiodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.Read More… 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Biodesix Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks62nd Percentile Overall ScoreBDSX MarketRank™: Biodesix scored higher than 62% of companies evaluated by MarketBeat, and ranked 433rd out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBiodesix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiodesix has only been the subject of 1 research reports in the past 90 days.Read more about Biodesix's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biodesix are expected to grow in the coming year, from ($0.36) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biodesix is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biodesix is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiodesix has a P/B Ratio of 26.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.29% of the outstanding shares of Biodesix have been sold short.Short Interest Ratio / Days to CoverBiodesix has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biodesix has recently decreased by 1.10%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiodesix does not currently pay a dividend.Dividend GrowthBiodesix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.29% of the outstanding shares of Biodesix have been sold short.Short Interest Ratio / Days to CoverBiodesix has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biodesix has recently decreased by 1.10%, indicating that investor sentiment is improving. News and Social Media1.6 / 5News Sentiment-0.17 News SentimentBiodesix has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Biodesix this week, compared to 1 article on an average week.Search Interest3 people have searched for BDSX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Biodesix to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Biodesix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,533.00 in company stock.Percentage Held by Insiders69.20% of the stock of Biodesix is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 20.96% of the stock of Biodesix is held by institutions.Read more about Biodesix's insider trading history. Receive BDSX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biodesix and its competitors with MarketBeat's FREE daily newsletter. Email Address BDSX Stock News HeadlinesBiodesix files to sell 62.2M shares of common stock for holdersNovember 1 at 9:28 PM | markets.businessinsider.comBiodesix: Poised for Recovery and Growth Amid Temporary SetbacksNovember 1 at 9:28 PM | markets.businessinsider.comCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!November 2, 2024 | Crypto 101 Media (Ad)Biodesix Announces Third Quarter 2024 Results and HighlightsNovember 1 at 6:00 AM | globenewswire.comCraig-Hallum Sticks to Its Buy Rating for Biodesix (BDSX)October 29, 2024 | markets.businessinsider.comBiodesix to Participate in Three Investor Conferences in NovemberOctober 29, 2024 | globenewswire.comBiodesix to Report Third Quarter 2024 Financial Results on November 1, 2024October 18, 2024 | businesswire.comBiodesix (NASDAQ:BDSX) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comSee More Headlines BDSX Stock Analysis - Frequently Asked Questions How have BDSX shares performed this year? Biodesix's stock was trading at $1.84 at the beginning of the year. Since then, BDSX stock has decreased by 29.3% and is now trading at $1.30. View the best growth stocks for 2024 here. How were Biodesix's earnings last quarter? Biodesix, Inc. (NASDAQ:BDSX) posted its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.01. The firm had revenue of $17.93 million for the quarter, compared to the consensus estimate of $16.05 million. Biodesix had a negative net margin of 73.08% and a negative trailing twelve-month return on equity of 505.95%. When did Biodesix IPO? Biodesix (BDSX) raised $76 million in an initial public offering (IPO) on Wednesday, October 28th 2020. The company issued 4,200,000 shares at $17.00-$19.00 per share. Morgan Stanley and William Blair acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. Who are Biodesix's major shareholders? Biodesix's top institutional shareholders include Perkins Capital Management Inc. (0.50%). Insiders that own company stock include Jack W Schuler, John Patience, Scott Hutton, Robin Harper Cowie, Gary Anthony Pestano, Ryan H Siurek, Kieran O'kane, Robert William Georgantas III, Chris Vazquez and Charles M Watts. View institutional ownership trends. How do I buy shares of Biodesix? Shares of BDSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Biodesix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biodesix investors own include Broadcom (AVGO), NVIDIA (NVDA), Adobe (ADBE), Arista Networks (ANET), ServiceNow (NOW), CrowdStrike (CRWD) and Meta Platforms (META). Company Calendar Last Earnings8/07/2024Today11/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:BDSX CUSIPN/A CIK1439725 Webwww.biodesix.com Phone303-417-0500FaxN/AEmployees220Year FoundedN/APrice Target and Rating Average Stock Price Target$3.06 High Stock Price Target$3.50 Low Stock Price Target$2.80 Potential Upside/Downside+135.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,150,000.00 Net Margins-73.08% Pretax Margin-73.08% Return on Equity-505.95% Return on Assets-44.09% Debt Debt-to-Equity Ratio0.99 Current Ratio3.28 Quick Ratio3.28 Sales & Book Value Annual Sales$49.09 million Price / Sales3.84 Cash FlowN/A Price / Cash FlowN/A Book Value$0.05 per share Price / Book26.00Miscellaneous Outstanding Shares145,180,000Free Float44,715,000Market Cap$188.73 million OptionableOptionable Beta1.22 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:BDSX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodesix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodesix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.